Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study - PubMed
6 hours ago
- #ctDNA
- #metastatic colorectal cancer
- #biomarker
- Circulating tumor DNA (ctDNA) serves as a minimally invasive biomarker for tumor burden and treatment response in metastatic colorectal cancer.
- The ALTER-C-002 study evaluated ctDNA levels and changes during treatment in RAS/BRAF wild-type metastatic colorectal cancer patients.
- Baseline ctDNA levels were higher in patients with liver-only metastasis.
- Significant ctDNA reduction was observed at the best radiologic response timepoint (C1), while an increase was seen at disease progression (C2).
- ctDNA negativity at C1 correlated with objective response and longer progression-free survival (PFS) and overall survival (OS).
- KRAS/BRAF mutations in ctDNA were associated with shorter PFS and OS.
- Baseline ctDNA burden and early clearance may serve as prognostic biomarkers for treatment efficacy.